dapt therapy - HEALTHY
Medscape: Short Aspirin Therapy Noninferior to DAPT for 1 Year After PCI for ACS Short Aspirin Therapy Noninferior to DAPT for 1 Year After PCI for ACS TCTMD: When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters The efficacy of P2Y12 monotherapy depends on the type of drug used after discontinuation of dual antiplatelet therapy (DAPT) for post-PCI patients, according to a new patient-level meta-analysis. When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters A shortened course of dual antiplatelet therapy (DAPT) after angioplasty was associated with reduced bleeding, with no significant uptick in ischemic events, over longer follow-up of the SMART-CHOICE ... When stopping dual antiplatelet therapy (DAPT) after PCI, it appears that a P2Y12 inhibitor is a better option than aspirin for continuing monotherapy, a network-meta-analysis suggests.
Context Explanation
The risk of MI ... Monthly Prescribing Reference: De-Escalating DAPT to Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome De-Escalating DAPT to Ticagrelor Monotherapy Cuts Bleeding Risk in Acute Coronary Syndrome While dual antiplatelet therapy (DAPT) has long been the standard of care for the management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), there is an ... Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not superior to dual-antiplatelet therapy (DAPT) for major bleeding but is non-inferior for ... DALLAS -- Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported.
Image Collection
Insight Material
In the ARAMIS trial of patients with acute ... Medscape: DAPT Trial: Extended Post-PCI Dual Antiplatelet Therapy Best in Patients With, Without ACS SAN DIEGO, CA — Compared with stopping dual antiplatelet therapy (DAPT) at 12 months, extending therapy to 30 months reduced the risk of stent thrombosis and MI but also increased the risk of mild to ... DAPT Trial: Extended Post-PCI Dual Antiplatelet Therapy Best in Patients With, Without ACS Three months of dual antiplatelet therapy (DAPT) was associated with signals suggesting improved survival and lower bleeding risk than 12 months of DAPT, in a real-world all-comer population of ...